We are live on ! Find out more
PAI

ProQuest Associates IV Portfolio holdings

AUM $53M
1-Year Est. Return 3.35%
This Fund
S&P 500
This Quarter Est. Return
-49.38%
1 Year Est. Return
+3.35%
3 Year Est. Return
+113.14%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$257M
AUM Growth
-$261M
Cap. Flow
+$2.01M
Cap. Flow %
0.78%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
1
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
AGRX
Agile Therapeutics
AGRX
+$2.54M

Top Sells

Rank Stock Value
1
SVRA icon
Savara
SVRA
+$536K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EGRX
1
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$194M 75.2%
4,780,188
– –
AGRX
2
DELISTED
Agile Therapeutics
AGRX
$31.4M 12.21%
2,531
+197
+8% +$2.54M
IMDZ
3
DELISTED
Immune Design Corp.
IMDZ
$25.5M 9.91%
1,962,720
– –
ANTH
4
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$6.88M 2.67%
237,500
– –
SVRA icon
5
Savara
SVRA
$1.08B
– –
-18,228
Closed -$536K

Similar funds

CCP
Centaur Capital Partners Southlake, Texas $54.1M AUM 12.4% 1-Year Est. Return
CLA
Cranberry Lake Advisors Houston, Texas $50.6M AUM 5.12% 1-Year Est. Return
HC
Hampstead Capital London, United Kingdom $55.8M AUM 2.76% 1-Year Est. Return
SF
Schooner Foundation Boston, Massachusetts $49.6M AUM 9.4% 1-Year Est. Return
DIV
DCM International V Menlo Park, California $47.8M AUM 19.52% 1-Year Est. Return
MGPI
Maveron General Partner III Seattle, Washington $46.7M AUM 35.29% 1-Year Est. Return
MCAI
Meritech Capital Associates III Palo Alto, California $45.8M AUM 24.9% 1-Year Est. Return
P
PhaseCapital New York $45.2M AUM 8.85% 1-Year Est. Return

ProQuest Associates IV's Q1 2016 Portfolio in Review

As of Q1 2016, ProQuest Associates IV held 5 positions worth $257M, down 50% from $518M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

ProQuest Associates IV's Q1 2016 filing shows 1 increased and 1 closed positions. The largest sale was Savara, an estimated $536K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • ProQuest Associates IV added most to Agile Therapeutics in Q1 2016, an estimated $2.54M increase.
  • ProQuest Associates IV fully exited Savara in Q1 2016, selling an estimated $536K.
  • ProQuest Associates IV's ten largest holdings make up 100% of its $257M portfolio in Q1 2016.
  • ProQuest Associates IV opened 0 new positions and closed 1 in Q1 2016.
  • ProQuest Associates IV's portfolio value fell 50% quarter-over-quarter to $257M.

Based on ProQuest Associates IV's 13F filing for Q1 2016, filed 13 May 2016.